atorvastatin / Generic mfg. - LARVOL DELTA

A Study to Assess the Effect of HRS-1301 on the Pharmacokinetics of Midazolam and Atorvastatin in Healthy Participants (clinicaltrials.gov) - P1 | N=16 | Completed | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Recruiting ➔ Completed

Trial completion • Dyslipidemia

Cost analysis of returned medicines at the outpatient pharmacy of a Malaysian state hospital. (PubMed, Med J Malaysia) - "Returned medicines lead to significant financial losses from both medication wastage and disposal for public providers. Shorter refill durations, medication adherence support, deprescribing and controls on highvalue ABC group A items could reduce wastage."

HEOR • Journal • Cardiovascular

Mandibular Trabecular Bone Microarchitecture in Statin-Treated Versus Statin-Naive Hyperlipidemic Patients. (PubMed, Niger J Clin Pract) - "Although FD values tended to be higher among participants receiving atorvastatin therapy, statistical significance was confined to the mandibular angle, where the absolute difference was small. Therefore, long-term atorvastatin use may be associated with a subtle, site-specific radiographic variation in mandibular trabecular architecture among individuals with hyperlipidemia."

Journal • Retrospective data • Dyslipidemia

Severe metabolic imbalance unveiled by eruptive xanthomas in Prader–Willi syndrome: a clinical case (EADV 2026) - "Therapeutic management included metformin and glibenclamide for glycemic control, along with ciprofibrate and atorvastatin for lipid reduction. Prompt recognition of these lesions allows early identification and treatment of potentially life-threatening metabolic disturbances. This case emphasizes the role of dermatological findings as a gateway to the diagnosis of systemic disease."

Clinical • Diabetes • Dyslipidemia • Hypertriglyceridemia • Metabolic Disorders • Obesity • Prader–Willi syndrome • Renal Disease • Severe Hypertriglyceridemia

IgG4-related disease: A diagnostic dilemma for 20 years (EADV 2026) - "His past medical history was significant for IgA nephropathy, resolved hepatitis B infection, hyperlipidaemia and hypertension and his only regular medication was atorvastatin...He is planned to be treated with prednisolone and rituximab, following clearance from hepatology clinicians, regarding hepatitis B reactivation risk, and from dental clinicians, to address the 4-8 tooth findings...Cutaneous manifestations can aid in early diagnosis by providing accessible histopathological evidence of disease. Given the trajectory of chronic inflammation and irreversible fibrosis demonstrated in this condition, greater awareness is warranted to reduce diagnostic delay and initiate early treatment."

Atherosclerosis • Cardiovascular • Dyslipidemia • Fibrosis • Glomerulonephritis • Hepatitis B • Hepatology • Hypertension • IgA Nephropathy • Infectious Disease • Inflammation • Ophthalmology • Renal Disease

Treatment-Refractory Darier Disease Flare Responsive to Upadacitinib (EADV 2026) - "Current medications included ticagrelor, atorvastatin, omega-3 supplements, vitamin B12, and occasional acetaminophen or ibuprofen...Acitretin, which had been increased from 25 mg to 50 mg daily due to the current flare did not lead to a sufficient response. Additional treatments included topical tazarotene, pyrithione zinc shampoo, roflumilast foam, and halobetasol propionate/tazarotene combination lotion (0.01%/0.045%), which all improved pruritus but did not lead to a sufficient response. He was subsequently started on cephalexin 500 mg four times daily for one week and topical ruxolitinib 1.5% once daily. A trial of low-dose naltrexone and topical 5-fluorouracil also did not lead to improvement...The significant clinical improvement observed after initiation of upadacitinib suggests that Janus Kinase (JAK) inhibition may represent a potential treatment option for recalcitrant Darier disease. Further studies are needed to demonstrate the efficacy and safety of..."

Cardiovascular • Coronary Artery Disease • Dermatology • Food Hypersensitivity • Genetic Disorders • Immunology • Musculoskeletal Diseases • Obesity • Orthopedics • Pruritus • Rosacea

TRICONOS: A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia (clinicaltrials.gov) - P=N/A | N=2000 | Active, not recruiting | Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Dyslipidemia • Metabolic Disorders • Mixed Hyperlipidemia

A herb-drug interaction: The role of transporters in the modulation of atorvastatin absorption by Compound Danshen Tablets. (PubMed, Drug Metab Dispos) - "In Caco-2 monolayers, ATV exhibited marked directional efflux, with an efflux ratio of 39.32, which was reduced to 10.99 by verapamil. SIGNIFICANT STATEMENT: This study identifies a clinically relevant herb-drug interaction in which repeated administration of compound Danshen tablets increases oral atorvastatin exposure in normal and hyperlipidemic/diabetic rats without materially altering intravenous atorvastatin pharmacokinetics. Integrated pharmacokinetic, single-pass intestinal perfusion, Caco-2 transport, human multidrug resistance protein 1 vesicle, ileal P-glycoprotein, and digoxin probe-substrate data support attenuation of intestinal P-glycoprotein-mediated efflux, through reduced transporter activity and protein abundance, as a mechanism enhancing atorvastatin absorption."

Journal • Diabetes • Dyslipidemia • Metabolic Disorders • Type 2 Diabetes Mellitus • ABCC1

Quality Over Quantity: Targeting Lipoprotein(a) Beyond Circulating Levels. (PubMed, JACC Basic Transl Sci) - No abstract available

Journal

Rates of Lipoprotein(a) Oxidation Accelerate at Elevated Levels and Attenuate With Atorvastatin Active Metabolites Compared With Other Statins. (PubMed, JACC Basic Transl Sci) - "The metabolites' unique phenoxy group facilitated membrane partitioning, leading to free radical scavenging activity as compared with other statins. The antioxidant actions of atorvastatin metabolites may reduce the atherogenicity of Lp(a) in patients independent of their levels."

Journal • Cardiovascular • Dyslipidemia • APOB

A flow cytometry-based assay system for the in vitro screening of anti-steatotic compounds. (PubMed, In Vitro Model) - "The assay was validated using known anti-steatotic drugs, where Saroglitazar, Pioglitazone, Empagliflozin, and Atorvastatin significantly reduced lipid accumulation in HepG2 cells. The present flow cytometry assay is a human cell-based and animal-free system that offers a sensitive, accurate, and high-throughput platform for evaluating anti-steatotic compounds, with clear advantages over conventional methods for early-stage drug discovery. The online version contains supplementary material available at https://doi.org/10.1007/s44164-026-00110-4."

Journal • Preclinical • Hepatology • Metabolic Dysfunction-Associated Steatotic Liver Disease

ATORVASTATIN FOR PREVENTION OF FIRST DECOMPENSATION IN HIGH-RISK COMPENSATED LIVER CIRRHOSIS: A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL — A PRELIMINARY REPORT (UEGW 2026) - "At this 24-week preliminary analysis, atorvastatin 20 mg daily demonstrated an acceptable safety profile in patients with high-risk compensated cirrhosis, without causing severe hepatotoxicity or clinically muscle injury, though it did not significantly improve liver stiffness relative to placebo. Mild, asymptomatic transaminitis were observed in the atorvastatin arm but did not necessitate treatment discontinuation. The diverging LSM trajectories and the absence of decompensation events in the atorvastatin arm represent an encouraging early biological signal."

Clinical • Cardiovascular • Fibrosis • Gastroenterology • Hepatitis B • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Liver Failure • Myositis • Portal Hypertension

Exploring the Therapeutic Effects of Artemisia rupestris L. Extract on Metabolic Dysfunction-Associated Fatty Liver Disease: Network Pharmacology and In Vitro Experiments. (PubMed, Pharmaceuticals (Basel)) - "In vitro, ARE dose-dependently reduced intracellular triglycerides, total cholesterol, and LDL-C, decreased lipid droplets, and lowered AST/ALT levels, with a high-dose efficacy comparable to atorvastatin. Through in vitro experiments and network pharmacology analyses, this study preliminarily elucidated the beneficial effects of ARE on lipid deposition in hepatocytes and its potential mechanism, thereby providing an experimental basis and potential avenues for subsequent in vivo studies on pharmacodynamics, pharmacokinetics, and toxicology."

Journal • Preclinical • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • AKR1B10 • MAPK14

The Effect of High-Dose Atorvastatin on Postoperative Troponin in Patients Undergoing Non-Cardiac Surgery: A Triple-Blind Randomized Clinical Trial. (PubMed, Res Heart Yield Transl Med) - "Preoperative high-dose atorvastatin significantly reduced postoperative hs-cTn levels, indicating a biochemical cardioprotective effect, but it did not translate into a reduction of short-term clinical cardiovascular events. Larger multicenter trials with longer follow-up are required to determine whether troponin reduction translates into improved clinical outcomes."

Clinical • Journal • Anesthesia • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction

The Influence of Statin Therapy on Markers of Endothelial Dysfunction, Endocan and Endoglin, in Postmenopausal Women-A Prospective Study. (PubMed, Biomedicines) - "ROC curve analysis demonstrated that neither biomarker had significant clinical discriminatory ability to predict the attainment of target LDL-C levels. Atorvastatin and rosuvastatin treatment was associated with significant reductions in plasma endocan and endoglin concentrations in postmenopausal women receiving primary cardiovascular prevention."

Journal • Cardiovascular • Dyslipidemia • Metabolic Disorders • ENG

Need for Medication Review and Deprescribing in People Living with HIV: A Longitudinal Observational Study. (PubMed, Pharmaceuticals (Basel)) - "Four were DDIs: cobicistat/alprazolam associated with sedation and dyspnoea, rilpivirine/hydroxychloroquine with QT prolongation, bictegravir/ursodeoxycholic acid with rising viremia, and atorvastatin/fenofibrate with myalgia...After medication review, alprazolam was replaced with zolpidem, rilpivirine-based HAART with bictegravir/emtricitabine/tenofovir alafenamide, and atorvastatin/fenofibrate with simvastatin/ezetimibe, and ursodeoxycholic acid and supplements were discontinued... This study highlights the importance of predicting DDIs/DSIs in PLWH undergoing polypharmacy. Medication review supports clinical decision-making, preventing avoidable adverse outcomes."

Journal • Observational data • Anesthesia • Human Immunodeficiency Virus • Infectious Disease • Musculoskeletal Pain • Pain • Pulmonary Disease

The Compatibility of Astragali Radix and Angelicae Sinensis Radix Attenuates Atherosclerosis by Suppressing Vascular Endothelial PANoptosis via the p38 MAPK/p53 Pathway: A Multi-Omics and Experimental Study. (PubMed, Int J Mol Sci) - "In vivo, male ApoE-deficient mice were allocated at random into the model cohort, AR-ASR low-, medium-, and high-dose groups (AR-ASR L, AR-ASR M, and AR-ASR H, respectively), atorvastatin group (ATV), and control group (age-matched wild-type C57BL/6J mice)...Furthermore, in the presence of a p38MAPK agonist, the inhibitory effects of AR-ASR on cellular PANoptosis and p38MAPK/p53 pathway activation were significantly attenuated. The AR-ASR compatibility suppresses p38MAPK/p53 pathway activation, thereby inhibiting vascular endothelial PANoptosis-driven inflammatory responses and ameliorating atherosclerotic vascular pathology."

Journal • Atherosclerosis • Cardiovascular • Inflammation • APOE

Development and In Vitro Evaluation of Atorvastatin and Rutin Co-Loaded Nanoliposomes for Enhanced Anti-Inflammatory and Cytotoxic Efficacy. (PubMed, Int J Mol Sci) - "These findings support further investigation of atorvastatin-rutin co-loaded nanoliposomes as an in vitro formulation platform; however, formal synergy analysis, cellular uptake studies, mechanistic assays, pharmacokinetic evaluation, and in vivo safety testing remain necessary. Further in vivo studies are required to determine pharmacokinetic behavior, tissue distribution, therapeutic relevance, and systemic safety."

Journal • Preclinical • Oncology

Generic Versus Branded Atorvastatin: A Single-Center Comparative Analysis of Clinical Effectiveness and Post-Delisting Cost Savings in Saudi Arabia. (PubMed, Healthcare (Basel)) - " Generic atorvastatin was found to have similar clinical effectiveness to the branded version in terms of reducing atherogenic lipids, with no statistically significant difference between the two groups. Furthermore, the economic modeling shows that using generic atorvastatin yields considerable national-level cost savings."

HEOR • Journal • Dyslipidemia • Metabolic Disorders

The Role of 5-HT1A and 5-HT7 Receptors in Anxiety-like Behavior in Mice Treated with Subchronic Atorvastatin. (PubMed, Curr Issues Mol Biol) - "In the second phase, the effect of serotonergic drugs (0.5 or 1 mg/kg of 8-OH-DPAT, a 5-HT1A/5-HT7 receptor agonist, or WAY100635, a 5-HT1A receptor antagonist) on anxiety-related behaviors was studied in separate groups of animals, stratified by dose, that had previously been treated with or without STA. The persistence of the anxiogenic effect following serotonergic drug administration in mice previously treated with STA may be related to the increased mRNA expression of 5-HT1AR and 5-HT7R observed in the hippocampus, striatum, and prefrontal cortex, although confirmation at the protein level is needed in future studies."

Journal • Preclinical • Mood Disorders • Psychiatry

When the Statin Strikes Twice: Atorvastatin-Induced Autoimmune Hepatitis Confirmed by Inadvertent Rechallenge (ACG 2026) - "Atorvastatin was discontinued, she received steroid with improvement, and she was transitioned to evolocumab. The lesson is twofold: an injury labeled DILI may in fact be drug-induced AIH, particularly with interface activity and low-titer antibodies, and such patients warrant close follow-up rather than reassurance alone. In the post-ACS patient, where high-intensity statins are routine, a prior statin hepatitis should be flagged across care transitions, with early use of a PCSK9 inhibitor to avoid a dangerous rechallenge."

Autoimmune Hepatitis • Hepatitis C • Hepatology • Immunology • Inflammation

Reducing Cardiovascular Risk in Patients With MASH Independent of Baseline Based on Lp(a) and LDL Lowering by Resmetirom (ACG 2026) - "Introduction: Patients with MASH have high CV morbidity and mortality. Approximately half (n = 473; 49%) of MAESTRO-NASH participants were on statins at baseline. Atorvastatin was the most commonly used statin (47.1%), and 26.9% of statin-treated patients were receiving high-intensity statin therapy. Baseline characteristics were generally similar across statin subgroups; however, a greater proportion of patients receiving statins, compared with those not receiving statins, had diabetes (79.5% vs 55.0%), dyslipidaemia (100% vs 43.8%), and advanced fibrosis (F3: 64.3% vs 56.6%) at baseline."

Clinical • Cardiovascular • Diabetes • Dyslipidemia • Fibrosis • Hepatology • Immunology • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • APOB

Lipophilic and Hydrophilic Statins Differentially Sensitize HepG2 Hepatocellular Carcinoma Cells to Sorafenib-Induced Cytotoxicity: An In-Vitro Study (ACG 2026) - "Sorafenib demonstrated an IC50 of 5.62 µg/mL. Atorvastatin and rosuvastatin showed antiproliferative activity against HepG2 cells, with IC50 values of 43.58 µg/mL and 50.92 µg/mL, respectively. In the presence of fixed-dose sorafenib, the IC50 of atorvastatin decreased to 30.46 µg/mL, while the IC50 of rosuvastatin decreased to 42.93 µg/mL."

Preclinical • Hepatocellular Cancer • Metabolic Disorders • Oncology • Solid Tumor

Microscopic Colitis Unmasked: A Treatable Mimic of Gastrointestinal Amyloidosis in Wild-Type ATTR Cardiac Amyloidosis (ACG 2026) - "We present a case of an ATTRwt patient with significant diarrhea found to have biopsy-proven lymphocytic colitis and negative Congo red staining.â¯â¯ Case Description/ An 84-year-old male with ATTRwt cardiac amyloidosis, diagnosed one year prior with a positive technetium pyrophosphate scan and negative genetic testing, now on Acoramidis, presented with chronic non-bloody diarrhea for 2 years...His medications included aspirin, metoprolol, atorvastatin, and pantoprazole...The robust response to budesonide supports microscopic colitis as the most likely etiology. As ATTRwt diagnosis becomes more frequent with increased disease awareness, recognizing co-occurring GI conditions will be essential to avoid misattribution and ensure targeted treatment.⯠Figure: Clinical Timeline: ATTRwt Cardiac Amyloidosis with Co-occurring Lymphocytic Colitis"

Amyloidosis • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Immunology

Progressive Hepatocellular Injury Revealing Secondary Adrenal Insufficiency (ACG 2026) - "Atorvastatin and divalproex sodium were discontinued without improvement in liver enzymes...Stress-dose hydrocortisone was initiated with rapid improvement in liver enzymes and metabolic abnormalities...In this case, infectious, autoimmune, vascular, and medication-related evaluation was unrevealing, while liver enzymes improved rapidly after corticosteroid replacement, strongly supporting adrenal insufficiency-associated liver injury. Adrenal insufficiency should be considered in patients with unexplained hepatocellular injury with hypoglycemia, electrolyte abnormalities, hypothyroidism, or pituitary disease."

Autoimmune Hepatitis • Bipolar Disorder • Cardiovascular • CNS Disorders • Endocrine Disorders • Heart Failure • Hepatology • Hypoglycemia • Hypotension • Immunology • Infectious Disease • Inflammation • Liver Failure • Nephrology • Pituitary Gland Carcinoma • Renal Disease • Vascular Neurology